Literature DB >> 16291835

Identification of novel protein targets for modification by 15-deoxy-Delta12,14-prostaglandin J2 in mesangial cells reveals multiple interactions with the cytoskeleton.

Konstantinos Stamatakis1, Francisco J Sánchez-Gómez, Dolores Pérez-Sala.   

Abstract

The cyclopentenone prostaglandin 15-deoxy-Delta12,14-PGJ2 (15d-PGJ2) has been shown to display protective effects against renal injury or inflammation. In cultured mesangial cells (MC), 15d-PGJ2 inhibits the expression of proinflammatory genes and modulates cell proliferation. Therefore, cyclopentenone prostaglandins (cyPG) have been envisaged as a promise in the treatment of renal disease. The effects of 15d-PGJ2 may be dependent on or independent from its role as a peroxisome proliferator-activated receptor agonist. It was shown recently that an important determinant for the peroxisome proliferator-activated receptor-independent effects of 15d-PGJ2 is the capacity to modify proteins covalently and alter their function. However, a limited number of protein targets have been identified to date. Herein is shown that a biotinylated derivative of 15d-PGJ2 recapitulates the effects of 15d-PGJ2 on the stress response and inhibition of inducible nitric oxide synthase levels and forms stable adducts with proteins in intact MC. Biotinylated 15d-PGJ2 was then used to identify proteins that potentially are involved in cyPG biologic effects. Extracts from biotinylated 15d-PGJ2-treated MC were separated by two-dimensional electrophoresis, and the spots of interest were analyzed by mass spectrometry. Identified targets include proteins that are regulated by oxidative stress, such as heat-shock protein 90 and nucleoside diphosphate kinase, as well as proteins that are involved in cytoskeletal organization, such as actin, tubulin, vimentin, and tropomyosin. Biotinylated 15d-PGJ2 binding to several targets was confirmed by avidin pull-down. Consistent with these findings, 15d-PGJ2 induced early reorganization of vimentin and tubulin in MC. The cyclopentenone moiety and the presence of cysteine were important for vimentin rearrangement. These studies may contribute to the understanding of the mechanism of action and therapeutic potential of cyPG.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291835     DOI: 10.1681/ASN.2005030329

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  34 in total

1.  Modulation of mammary cancer cell migration by 15-deoxy-delta(12,14)-prostaglandin J(2): implications for anti-metastatic therapy.

Authors:  Anne R Diers; Brian P Dranka; Karina C Ricart; Joo Yeun Oh; Michelle S Johnson; Fen Zhou; Manuel A Pallero; Thomas M Bodenstine; Joanne E Murphy-Ullrich; Danny R Welch; Aimee Landar
Journal:  Biochem J       Date:  2010-08-15       Impact factor: 3.857

2.  Identification of potential protein targets of isothiocyanates by proteomics.

Authors:  Lixin Mi; Brian L Hood; Nicolas A Stewart; Zhen Xiao; Sudha Govind; Xiantao Wang; Thomas P Conrads; Timothy D Veenstra; Fung-Lung Chung
Journal:  Chem Res Toxicol       Date:  2011-08-26       Impact factor: 3.739

Review 3.  Protein damage by reactive electrophiles: targets and consequences.

Authors:  Daniel C Liebler
Journal:  Chem Res Toxicol       Date:  2007-12-04       Impact factor: 3.739

4.  Prostaglandin E2 modifies SMAD2 and promotes SMAD2-SMAD4 complex formation.

Authors:  Chen Yang; Chen Chen; Andrey Sorokin
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2014-02-26       Impact factor: 4.006

5.  Antinociceptive activity of CC44, a biotinylated improgan congener.

Authors:  Paul Hoerbelt; Julia W Nalwalk; James G Phillips; Mark P Wentland; Zhixing Shan; Lindsay B Hough
Journal:  Eur J Pharmacol       Date:  2013-07-05       Impact factor: 4.432

6.  15-Deoxy-Delta12,14-prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification.

Authors:  Parisa Kalantari; Vivek Narayan; Andrew J Henderson; K Sandeep Prabhu
Journal:  FASEB J       Date:  2009-03-19       Impact factor: 5.191

7.  Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia.

Authors:  Farhat L Khanim; Rachel E Hayden; Jane Birtwistle; Alessia Lodi; Stefano Tiziani; Nicholas J Davies; Jon P Ride; Mark R Viant; Ulrich L Gunther; Joanne C Mountford; Heinrich Schrewe; Richard M Green; Jim A Murray; Mark T Drayson; Chris M Bunce
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

8.  Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice.

Authors:  Sha-Ron Pierre; Marijke A M Lemmens; Maria E Figueiredo-Pereira
Journal:  J Neuroinflammation       Date:  2009-07-25       Impact factor: 8.322

Review 9.  Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration.

Authors:  Maria E Figueiredo-Pereira; Chuhyon Corwin; John Babich
Journal:  Ann N Y Acad Sci       Date:  2016-01-08       Impact factor: 5.691

10.  15-Deoxy-Delta(12,14)-prostaglandin-J(2) reveals a new pVHL-independent, lysosomal-dependent mechanism of HIF-1alpha degradation.

Authors:  Gemma Olmos; María I Arenas; Raquel Bienes; María Jose Calzada; Julián Aragonés; Maria Laura Garcia-Bermejo; Manuel O Landazuri; Javier Lucio-Cazaña
Journal:  Cell Mol Life Sci       Date:  2009-05-21       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.